On August 4, Krystal Biotech Inc. rose 5.04% in regular trading, trading at approximately $328.31/share, with turnover of $119 million. The rebound follows a sharp sell-off of over 9% in the prior session after the company released its Q2 earnings report.

On the news front, while the stock initially plunged on revenue concerns, the market subsequently refocused on strong profitability metrics. Q2 earnings per share came in at $1.79, significantly beating the consensus estimate of $1.62. Net income rose to $54.8 million, representing a 43% year-over-year increase. However, flagship product VYJUVEK posted global net sales of $119.2 million, falling short of the $122 million consensus, with 24% year-over-year growth below the expected 32.72%. The limited sequential growth from Q1 revenue of $116.4 million had initially raised concerns about commercial ramp trajectory, particularly given the stock's prior run-up following inclusion in the S&P MidCap 400 index in late July.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)